Justice Stellios, sitting as duty judge in the Federal Court of Australia, has granted a mandatory interlocutory injunction requiring RedTail Technology Pty Ltd and its founder and sole director, secretary and shareholder (Richard Pahlavani).
The Full Court of the Federal Court of Australia has delivered its decision in NOCO’s appeal from the primary judge’s decision in The NOCO Company v Brown and Watson International Pty Ltd [2025] FCA 887. The Full Court has dismissed NOCO’s appeal, rejecting NOCO’s challenges on lack of inventive step and the correct priority date for assessing novelty.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 10 July 2026 are set out below…
Shanghai Lytone Biochemicals has failed in its opposition to the grant of Fresh Inset S.A.’s patent application for compositions and articles comprising complexes of 1-methylcyclopropene (1-MCP) and alpha-cyclodextrin (α-CD), which are used to prolong the shelf life of plant products by inhibiting the effects of ethylene.
Pearce IP is pleased to welcome Sarah Dieckmann as an Associate and Foreign Registered Patent Attorney, further strengthening the firm’s specialist capability in biotechnology and life sciences intellectual property.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 3 July 2026 are set out below…
In v2food v Provectus, the Federal Court allowed v2food’s appeal after the opponent filed no evidence and took no active role in the appeal. Although the APO had previously found the claims lacked inventive step, the Court confirmed that on a de novo appeal the opponent still bears the onus — and without evidence, the opposition must fail.
Pearce IP is proud to be recognised by Australasian Lawyer and NZ Lawyer as a Top Specialist Firm in Intellectual Property for 2026 – marking its second consecutive year of recognition. Pearce IP was one of only six firms ranked in intellectual property, and the only standalone IP firm operating across both Australia and New Zealand.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 26 June 2026 are set out below…
Pearce IP continues to deliver on its commitment to set the standard for excellence in the provision of legal and intellectual property services across Australia and New Zealand with the appointment of Sarah Ramsey-Caudle as Senior Associate, Trade Mark Lawyer (AU) and Trade Mark Attorney (AU, NZ).
4 Pearce IP Patent Professionals Ranked in Managing IP’S IP STARS 2026, including Naomi Pearce and Helen Macpherson, who have been named Patent Stars in Australia; and Jacinta Flattery-O’Brien (Australia), and Paul Johns (New Zealand), who have been recognised as Notable Practitioners.
Pearce IP has been ranked by Managing IP in the 2026 Asia-Pacific IP Stars for Patent Prosecution, Patent Disputes and Trade Mark Prosecution, marking the sixth consecutive year of rankings for the Australian office and the first for Pearce IP New Zealand which was founded in 2024.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 June 2026 are set out below…
Pearce IP is pleased to announce the appointment of Peter O’Sullivan as Executive, Deputy CEO & Head of People and Culture. Peter is an experienced C-suite professional services executive, and joins Pearce IP with more than 30 years’ experience spanning human resources, business and law.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 12 June 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 5 June 2026 are set out below…
On 2 June 2026 the New Zealand Parliament passed an amendment to the Patents Act 2013 (2013 Act). The 2013 Act replaced the Patents Act 1953. The 2013 Act included transitional provisions that allowed patent applications filed under the 1953 Act, and any divisional patent applications relating to them, to be considered under the earlier and more lenient 1953 Act.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 29 May 2026 are set out below…
Pearce IP and 5 Leaders Ranked in IAM Patent 1000 2026 for AU and NZ Patent Prosecution and Litigation. 2026 marks the sixth consecutive year of Pearce IP IAM Patent 1000 ranking in Australia, one of only 51 law firms this year. Pearce IP also been ranked by IAM Patent 1000 for New Zealand every year since launching in New Zealand in 2024 and is one of only 17 firms listed this year.
Pearce IP Ranked in 2027 ‘Best Law Firms Australia’ for Life Sciences & Intellectual Property. Published by Best Lawyers and underpinned by a rigorous methodology, the Best Law Firms – Australia is in its third edition. This is the second time Pearce IP has been recognised, with rankings in both Life Sciences and IP.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 22 May 2026 are set out below…
Pearce IP is pleased to release the Annual Australian Patent Case Review 2025, a comprehensive, expert analysis of all key patent decisions shaping the Australian legal landscape over the past year. Spanning 130 pages, this essential resource provides a complete overview of: All decisions delivered by the Federal Court of Australia, All decisions delivered by the Full Court on appeal & Significant decisions from the Australian Patent Office
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 15 May 2026 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 8 May 2026 are set out below…
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
